MarginsXMarginsX
Home › Markets › Health Care › JANX

Janux Therapeutics Inc. (JANX)

JANX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.92
-3.96% on the day
Market cap
$668.1M
Small cap
Revenue · 2025
$10.0M
-5.6% on 2024
Net income · 2025
-$113.6M
-1136.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1817713/000119312526076918/0001193125-26-076918-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerJANX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001817713
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$10.0M
Net income-$113.6M
Operating income-$157.7M
Net margin-1136.3%
Operating margin-1576.7%
Revenue growth-5.6%
Cash$52.3M
Total assets$1.0B
P/E (computed)Net income was not positive
P/S (computed)66.8×

Warning signs

Cash runway
9.4 months
$41.8M cash at September 30, 2026
Share count, 1 year
+1.7%
2025-11-04 to 2026-11-03 · +32.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$41.8M cash; operating cash flow -$13.4M a quarter.Report 2026-09-30
Shares outstanding61,183,417 (2026-11-03); 60,147,807 a year earlier; 46,168,430 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$9.3M-$21.6M-$25.2M$41.8MNo debt tags$23.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$10.3M-$22.0M$12.5M$27.8MNo debt tags$24.0M10-Q 2026-08-06
Q1 2026
2026-03-31
$3.7M-$24.4M-$12.3M$51.8MNo debt tags$13.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$0-$31.9M-$28.5M$52.3MNo debt tags$10.0M10-K 2026-02-26
Q3 2025
2025-09-30
$10.0M-$24.3M-$12.9M$48.4MNo debt tags$10.0M10-Q 2026-11-05
Q2 2025
2025-06-30
$0-$33.9M-$23.8M$52.4MNo debt tags$439K10-Q 2026-08-06
Q1 2025
2025-03-31
$0-$23.5M-$17.0M$73.7MNo debt tags$9.3M10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$20.2M-$16.7M$430.6MNo debt tags$10.6M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-12-05
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 443 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-35.5%
1 month-33.8%
3 months-28.9%
Year to date-17.6%
1 year-58.6%
From 52-week high-67.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ALMSAlumis Inc.$5.14-8.21%$667.3M
APMDApnimed Inc.$16.28-3.78%$677.7M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
ANNXAnnexon Inc.$3.57-8.93%$681.0M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier